The goal of this study was to analyze case study data that suggests the value of adding CA11-19 to monitoring patients at risk of recurrence of colorectal cancer.
- Luminex, EDP Biotech Ink Deal for Colorectal Cancer Early Detection Blood Test
- EDP Biotech to Develop and Market Colorectal Cancer Early Detection Blood Test Using Luminex xMAP® Technology
- Large crowd attends EDP BioTech open house, spotlight on colorectal awareness
- Light on a dark subject: EDP aims to ease colon cancer testing
- Making Up for Unfavorable Reimbursement